novartis ag holding in intercell increases after vaccine accord novartis ag said it deepened its partnership with austria based biotechnology company intercell ag a step aimed at enhancing the swiss pharmaceutical companys position in the vaccine market novartis will increase its holding in intercell to from and make an up front payment of million euros &# million for opt in rights for continuing vaccine projects and potential vaccine candidates the move comes after novartis in signed a marketing and distribution agreement with intercell for ic a vaccine in trials for use in preventing infections from the japanese encephalitis virus the global vaccines market is one of the fastest growing in pharmaceuticals 
